Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082945900> ?p ?o ?g. }
- W3082945900 endingPage "4135" @default.
- W3082945900 startingPage "4124" @default.
- W3082945900 abstract "Bromodomain and extra-terminal domain (BET) proteins, cyclic adenosine monophosphate response element-binding protein (CBP), and the E1A-binding protein of p300 (EP300) are important players in histone acetylation. Preclinical evidence supports the notion that small molecules targeting these proteins individually or in combination can elicit antitumor activity. Here, we characterize the antitumor activity of the pan BET/CBP/EP300 inhibitor NEO2734 and provide insights into its mechanism of action through bromodomain-binding assays, in vitro and in vivo treatments of cancer cell lines, immunoblotting, and transcriptome analyses. In a panel of 60 models derived from different tumor types, NEO2734 exhibited antiproliferative activity in multiple cell lines, with the most potent activity observed in hematologic and prostate cancers. Focusing on lymphoma cell lines, NEO2374 exhibited a pattern of response and transcriptional changes similar to lymphoma cells exposed to either BET or CBP/EP300 inhibitors alone. However, NEO2734 was more potent than single-agent BET or CBP/EP300 inhibitors alone. In conclusion, NEO2734 is a novel antitumor compound that shows preferential activity in lymphomas, leukemias, and prostate cancers." @default.
- W3082945900 created "2020-09-08" @default.
- W3082945900 creator A5009234092 @default.
- W3082945900 creator A5011647120 @default.
- W3082945900 creator A5012537023 @default.
- W3082945900 creator A5015082674 @default.
- W3082945900 creator A5020962624 @default.
- W3082945900 creator A5033477524 @default.
- W3082945900 creator A5038420682 @default.
- W3082945900 creator A5039188583 @default.
- W3082945900 creator A5043985252 @default.
- W3082945900 creator A5048622832 @default.
- W3082945900 creator A5053703215 @default.
- W3082945900 creator A5059963876 @default.
- W3082945900 creator A5061285204 @default.
- W3082945900 creator A5063089135 @default.
- W3082945900 creator A5064713685 @default.
- W3082945900 creator A5065110620 @default.
- W3082945900 creator A5066518317 @default.
- W3082945900 creator A5067082936 @default.
- W3082945900 creator A5077930649 @default.
- W3082945900 date "2020-09-03" @default.
- W3082945900 modified "2023-10-01" @default.
- W3082945900 title "Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734" @default.
- W3082945900 cites W1625383933 @default.
- W3082945900 cites W1945410182 @default.
- W3082945900 cites W1971382122 @default.
- W3082945900 cites W1985118687 @default.
- W3082945900 cites W1994305150 @default.
- W3082945900 cites W2001619812 @default.
- W3082945900 cites W2002395443 @default.
- W3082945900 cites W2003262666 @default.
- W3082945900 cites W2004172747 @default.
- W3082945900 cites W2044352858 @default.
- W3082945900 cites W2044874589 @default.
- W3082945900 cites W2052787205 @default.
- W3082945900 cites W2056936324 @default.
- W3082945900 cites W2059145105 @default.
- W3082945900 cites W2063887542 @default.
- W3082945900 cites W2103441770 @default.
- W3082945900 cites W2109378990 @default.
- W3082945900 cites W2130410032 @default.
- W3082945900 cites W2137429553 @default.
- W3082945900 cites W2141242243 @default.
- W3082945900 cites W2168133698 @default.
- W3082945900 cites W2195303995 @default.
- W3082945900 cites W2238488506 @default.
- W3082945900 cites W2239381098 @default.
- W3082945900 cites W2294961516 @default.
- W3082945900 cites W2299219969 @default.
- W3082945900 cites W2300442403 @default.
- W3082945900 cites W2376907976 @default.
- W3082945900 cites W2417483443 @default.
- W3082945900 cites W2471089142 @default.
- W3082945900 cites W2523675873 @default.
- W3082945900 cites W2544359401 @default.
- W3082945900 cites W2571046561 @default.
- W3082945900 cites W2731003977 @default.
- W3082945900 cites W2748520706 @default.
- W3082945900 cites W2758743773 @default.
- W3082945900 cites W2765262832 @default.
- W3082945900 cites W2779743226 @default.
- W3082945900 cites W2786169577 @default.
- W3082945900 cites W2803008706 @default.
- W3082945900 cites W2904518824 @default.
- W3082945900 cites W2907783470 @default.
- W3082945900 cites W2912969574 @default.
- W3082945900 cites W2941404034 @default.
- W3082945900 cites W2952006126 @default.
- W3082945900 cites W2952176762 @default.
- W3082945900 cites W2953873379 @default.
- W3082945900 cites W2954517278 @default.
- W3082945900 cites W2968953400 @default.
- W3082945900 cites W2973058496 @default.
- W3082945900 cites W2976879024 @default.
- W3082945900 cites W2980844549 @default.
- W3082945900 cites W2984431814 @default.
- W3082945900 cites W2985548682 @default.
- W3082945900 cites W2999664171 @default.
- W3082945900 cites W3004198684 @default.
- W3082945900 cites W3013817962 @default.
- W3082945900 cites W3021366882 @default.
- W3082945900 cites W3031552265 @default.
- W3082945900 cites W3043480372 @default.
- W3082945900 cites W3091080161 @default.
- W3082945900 cites W3180646540 @default.
- W3082945900 cites W4206707998 @default.
- W3082945900 doi "https://doi.org/10.1182/bloodadvances.2020001879" @default.
- W3082945900 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7479962" @default.
- W3082945900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32882003" @default.
- W3082945900 hasPublicationYear "2020" @default.
- W3082945900 type Work @default.
- W3082945900 sameAs 3082945900 @default.
- W3082945900 citedByCount "29" @default.
- W3082945900 countsByYear W30829459002020 @default.
- W3082945900 countsByYear W30829459002021 @default.
- W3082945900 countsByYear W30829459002022 @default.
- W3082945900 countsByYear W30829459002023 @default.